EP 168: A world-first in RNA medicines with Erik Ingelsson, CSO at Wave Life Sciences скачать в хорошем качестве

EP 168: A world-first in RNA medicines with Erik Ingelsson, CSO at Wave Life Sciences

Happy New Year! In our first episode of 2025, Patrick is joined by Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences. Erik is also the formerr Senior Vice President of Target Discovery at GlaxoSmithKline and a former Professor at Stanford and Uppsala universities. Patrick and Erik discuss Wave’s world-first discovery in RNA editing therapies for Alpha-1 Antitrypsin Deficiency (AATD), Erik’s far-reaching career across academia, big pharma and biotech, and how to be a present parent in the thick of a thriving career. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Erik 02:05 Key differences between DNA and RNA editing 05:25 Wave’s recent world-first finding in Alpha-1 Antitrypsin Deficiency 08:17 Dosage regularity and delivery process for edited RNA therapies 14:08 Next steps for Wave’s new discovery, including potential applications in other conditions 17:41 Using genetic targets to inform areas of focus and RNA treatment development 24:04 The GLP1 mechanism in human genetics and its role in obesity 25:43 Erik’s transition from big pharma to biotech and the resulting changes in his approach to treatment development 31:02 What has driven Erik to explore and experience a wide range of roles throughout his career 34:29 The importance of balancing fatherhood with a thriving career, and how Erik works to do so successfully 38:35 Closing remarks Find out more wavelifesciences.com Erik Ingelsson Please consider rating and reviewing us on your chosen podcast listening platform!